Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry.
Clemente T, Diotallevi S, Minisci D, Di Biagio A, Lolatto R, Attala L, Cenderello G, Siribelli A, Muccini C, Lo Caputo S, Tavio M, Papaioannu Borjesson R, Giacomelli A, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. Among authors: spagnuolo v. J Antimicrob Chemother. 2024 Dec 27:dkae465. doi: 10.1093/jac/dkae465. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39727173
Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry.
Clemente T, Diotallevi S, Lolatto R, Gagliardini R, Giacomelli A, Fiscon M, Ferrara M, Cervo A, Calza L, Maggiolo F, Rusconi S, Santoro MM, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. Among authors: spagnuolo v. Int J Antimicrob Agents. 2024 Jul;64(1):107195. doi: 10.1016/j.ijantimicag.2024.107195. Epub 2024 May 9. Int J Antimicrob Agents. 2024. PMID: 38734216 No abstract available.
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry.
Mazzitelli M, Pontillo D, Clemente T, Di Biagio A, Cenderello G, Rusconi S, Menzaghi B, Fornabaio C, Garlassi E, Zazzi M, Castagna A, Cattelan AM; PRESTIGIO Study Group. Mazzitelli M, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2163-2169. doi: 10.1093/jac/dkae190. J Antimicrob Chemother. 2024. PMID: 39001781
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marchegiani G, Clemente T, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM; PRESTIGIO Study Group. Armenia D, et al. Among authors: spagnuolo v. J Antimicrob Chemother. 2024 Sep 3;79(9):2354-2363. doi: 10.1093/jac/dkae236. J Antimicrob Chemother. 2024. PMID: 39004997
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting.
Papaioannu Borjesson R, Clemente T, Diotallevi S, Lolatto R, Forniti A, Bottanelli M, Galli L, Gianotti N, Muccini C, Hasson H, Castagna A, Spagnuolo V. Papaioannu Borjesson R, et al. Among authors: spagnuolo v. J Antimicrob Chemother. 2024 Nov 21:dkae420. doi: 10.1093/jac/dkae420. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39568118
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment.
Spagnuolo V, Cocorullo D, Galli L, Bigoloni A, Galli A, Rubinacci A, Mignogna G, Carbone A, Lazzarin A, Castagna A. Spagnuolo V, et al. J Antimicrob Chemother. 2013 Dec;68(12):2960-3. doi: 10.1093/jac/dkt264. Epub 2013 Jun 27. J Antimicrob Chemother. 2013. PMID: 23812682 No abstract available.
Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
Castagna A, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, Nozza S, Racca S, Galli A, Cinque P, Carini E, Lazzarin A. Castagna A, et al. Among authors: spagnuolo v. J Antimicrob Chemother. 2019 Jul 1;74(7):2039-2046. doi: 10.1093/jac/dkz138. J Antimicrob Chemother. 2019. PMID: 31225610
Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study).
Mastrangelo A, Burbelo PD, Galli L, Poli A, Alteri C, Scutari R, Muccini C, Spagnuolo V, Caccia R, Turrini F, Bigoloni A, Galli A, Castagna A, Cinque P. Mastrangelo A, et al. Among authors: spagnuolo v. J Antimicrob Chemother. 2021 May 12;76(6):1646-1648. doi: 10.1093/jac/dkab060. J Antimicrob Chemother. 2021. PMID: 33693943 Free PMC article. No abstract available.
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
Saladini F, Giammarino F, Maggiolo F, Ferrara M, Cenderello G, Celesia BM, Martellotta F, Spagnuolo V, Corbelli GM, Gianotti N, Santoro MM, Rusconi S, Zazzi M, Castagna A; PRESTIGIO Study Group. Saladini F, et al. Among authors: spagnuolo v. Int J Antimicrob Agents. 2023 Mar;61(3):106737. doi: 10.1016/j.ijantimicag.2023.106737. Epub 2023 Jan 25. Int J Antimicrob Agents. 2023. PMID: 36708743
234 results